Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
10,470
+220 (2.15%)
At close: Apr 8, 2026
KRX:019170 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 47,433 | 41,986 | 43,800 | 41,691 | 27,637 |
Short-Term Investments | 24,073 | 14,475 | 16,245 | 14,226 | 64,599 |
Trading Asset Securities | - | - | 535.69 | - | 465.97 |
Cash & Short-Term Investments | 71,506 | 56,461 | 60,581 | 55,917 | 92,702 |
Cash Growth | 26.65% | -6.80% | 8.34% | -39.68% | -51.37% |
Accounts Receivable | 72,538 | 70,163 | 73,661 | 82,289 | 81,865 |
Other Receivables | 784.1 | 2,155 | 8,083 | 8,081 | 7,860 |
Receivables | 73,528 | 72,523 | 81,945 | 90,576 | 89,925 |
Inventory | 58,476 | 55,382 | 53,923 | 46,895 | 47,707 |
Prepaid Expenses | 1,225 | 2,757 | 766.58 | 1,008 | 900.48 |
Other Current Assets | 2,001 | 2,199 | 1,719 | 2,147 | 1,764 |
Total Current Assets | 206,736 | 189,321 | 198,935 | 196,542 | 232,997 |
Property, Plant & Equipment | 108,728 | 115,398 | 118,638 | 113,760 | 116,884 |
Long-Term Investments | 23,082 | 24,896 | 21,107 | 29,336 | 28,571 |
Other Intangible Assets | 5,086 | 5,006 | 5,769 | 6,931 | 8,971 |
Long-Term Deferred Tax Assets | 1,087 | 2,826 | 475.25 | 6,628 | 9,086 |
Other Long-Term Assets | 7,741 | 4,633 | 5,159 | 8,339 | 1,841 |
Total Assets | 352,466 | 342,093 | 350,084 | 361,536 | 398,350 |
Accounts Payable | 7,097 | 9,998 | 8,941 | 11,428 | 12,060 |
Accrued Expenses | 6,407 | 9,021 | 13,856 | 7,300 | 7,057 |
Short-Term Debt | 41,191 | 47,305 | 45,000 | - | 248.11 |
Current Portion of Long-Term Debt | 2,400 | 1,400 | - | - | - |
Current Portion of Leases | 764.99 | 951.49 | 932.48 | 1,487 | 719.94 |
Current Income Taxes Payable | 300 | 112.5 | 118.11 | - | 133.02 |
Other Current Liabilities | 8,750 | 7,056 | 7,537 | 6,952 | 8,332 |
Total Current Liabilities | 66,909 | 75,844 | 76,385 | 27,167 | 28,550 |
Long-Term Debt | 11,374 | 4,600 | - | - | - |
Long-Term Leases | 126.18 | 340.84 | 218.96 | 441.51 | 212.67 |
Pension & Post-Retirement Benefits | - | - | - | - | 7,065 |
Other Long-Term Liabilities | 3,329 | 3,218 | 2,698 | 3,169 | 2,197 |
Total Liabilities | 81,739 | 84,003 | 79,301 | 30,778 | 38,025 |
Common Stock | 27,592 | 27,592 | 27,592 | 27,592 | 27,592 |
Additional Paid-In Capital | 215,780 | 213,592 | 213,592 | 213,592 | 213,592 |
Retained Earnings | 50,771 | 38,943 | 55,331 | 115,830 | 144,925 |
Treasury Stock | -8,734 | -8,734 | -8,734 | -8,734 | -8,734 |
Comprehensive Income & Other | -15,434 | -14,573 | -18,196 | -18,673 | -18,118 |
Total Common Equity | 269,975 | 256,821 | 269,586 | 329,607 | 359,257 |
Minority Interest | 752.64 | 1,269 | 1,196 | 1,151 | 1,067 |
Shareholders' Equity | 270,728 | 258,090 | 270,782 | 330,758 | 360,324 |
Total Liabilities & Equity | 352,466 | 342,093 | 350,084 | 361,536 | 398,350 |
Total Debt | 55,856 | 54,597 | 46,151 | 1,928 | 1,181 |
Net Cash (Debt) | 15,650 | 1,864 | 14,430 | 53,988 | 91,521 |
Net Cash Growth | 739.66% | -87.08% | -73.27% | -41.01% | -51.54% |
Net Cash Per Share | 305.02 | 36.46 | 281.49 | 1053.18 | 1785.35 |
Filing Date Shares Outstanding | 51.3 | 49.27 | 49.27 | 49.27 | 49.27 |
Total Common Shares Outstanding | 51.3 | 51.26 | 51.26 | 51.26 | 51.26 |
Working Capital | 139,826 | 113,477 | 122,550 | 169,375 | 204,447 |
Book Value Per Share | 5262.54 | 5009.93 | 5258.95 | 6429.82 | 7008.22 |
Tangible Book Value | 264,889 | 251,814 | 263,817 | 322,676 | 350,286 |
Tangible Book Value Per Share | 5163.41 | 4912.27 | 5146.41 | 6294.62 | 6833.22 |
Land | 15,976 | 15,976 | 15,976 | 15,976 | 15,976 |
Buildings | 123,280 | 121,660 | 120,117 | 121,946 | 123,266 |
Machinery | 114,296 | 112,867 | 103,969 | 104,000 | 104,224 |
Construction In Progress | 762.97 | 1,124 | 5,426 | 4,231 | 329.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.